Publications by authors named "M Sabatiello"
Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients.
Expert Rev Clin Immunol
September 2021
Article Synopsis
- Psoriasis affects about 2% of children in Europe, with most cases manageable through topical corticosteroid treatments, while more severe cases may need phototherapy or systemic drugs that can have serious side effects.
- Over the past 15 years, several biologic treatments have been developed for moderate-to-severe plaque psoriasis, starting with etanercept and later including adalimumab, ustekinumab, secukinumab, and ixekizumab, which show better efficacy and safety compared to traditional therapies.
- Experts recommend ustekinumab, secukinumab, and ixekizumab as first-line treatments for moderate-to-severe psoriasis in children and adolescents due to their excellent outcomes and lower risk of adverse effects.
This is the case report of a 57-year-old women with a 10-year long history of urticarial-like exanthema and monoclonal immunoglobulin M Kappa gammopathy, associated to arthralgia with pain of the lower limbs. A cutaneous biopsy and an inflammatory syndrome on laboratory testing helped to diagnose an urticarial vasculitis. A treatment with colchicine was set up but the response to therapy was not satisfactory.
View Article and Find Full Text PDFThe TNFalpha antagonists, including adalimumab, etanercept and infliximab, represent a class of anti-inflammatory and immunosuppressive drugs. Although cutaneous adverse effects are uncommon, they are varied. There is no particular risk profile to develop cutaneous adverse effects.
View Article and Find Full Text PDFPemetrexed-induced pityriasis lichenoides-like dermatitis.
J Eur Acad Dermatol Venereol
January 2012